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Abstract
Heavy proteinuria with or without features of nephrotic syndrome is associated with many primary and systemic diseases. For
diabetic patients, distinguishing nondiabetic renal disease (NDRD) from diabetic nephropathy (DN) is important in choosing treatment
modalities and determining renal prognosis. However, clinical relevance of heavy proteinuria is inconsistent with clinical DN
assessments. This study investigated the clinicopathological features and renal outcomes of DN and NDRD in type 2 diabetic
patients with nephrotic-range proteinuria.
We enrolled 220 cases of type 2 diabetic patients who underwent renal biopsy. They were grouped according to the presence of
nephritic-range proteinuria and pathological features. Baseline characteristics, laboratory ﬁndings, types of pathological diagnosis,
and renal outcomes were analyzed in patients with heavy proteinuria.
Upon kidney biopsy, 129 patients (58.6%) showed nephritic-range proteinuria. Patients with heavy proteinuria (an average urine
protein-to-creatinine ratio of 10,008±7307mg/gCr) showed lower serum albumin levels and higher total cholesterol levels, but did
not show any difference in age, duration of diabetes, renal function, or the presence of retinopathy compared with those with mild-to-
moderate proteinuria (an average urine protein-to-creatinine ratio of 1581±979mg/gCr). Renal biopsy revealed that the prevalence
of NDRD was 37.2% in patients with heavy proteinuria, which was signiﬁcantly lower than that in patients with mild-to-moderate
proteinuria (63.7%). The most common pathological types of NDRD were membranous nephropathy (41.7%), IgA nephropathy
(14.6%), and minimal change disease (10.4%). NDRD patients showed lower prevalence of diabetic retinopathy and better kidney
function irrespective of proteinuria. Immunosuppressive treatment was administered more frequently in patients with heavy
proteinuria (56.3%) compared with patients with mild-to-moderate proteinuria (20%) because of the pathological differences
according to the amount of proteinuria. Renal outcomes were signiﬁcantly worse in patients with DN than in patients with NDRD.
DN patients with heavy proteinuria exhibited different prevalence of NDRD and worse prognosis. Renal biopsy in type 2 diabetic
patients should be more extensively considered to accurately diagnose NDRD, guide further management, and predict renal
outcomes, especially in patients with nephrotic-range proteinuria.
Abbreviations: NDRD = nondiabetic renal disease, DN = diabetic nephropathy.
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Diabetic kidney disease, traditionally termed diabetic nephropa-
thy (DN), is the leading cause of end-stage renal disease (ESRD)
worldwide. Despite major advances in medical care for diabetes
mellitus (DM), the prevalence of DN among diabetic patients has
not decreased over the last 3 decades.[1,2]Moreover, the incidence
of biopsy-proven DN is rapidly increasing, requiring further
insight into its pathogenesis and novel therapeutic options.[3]
The natural course of DN has traditionally been described to
be predictable; initial glomerular hyperperfusion is followed by
microalbuminuria, overt proteinuria, and eventually progressive
renal dysfunction. Accordingly, proteinuria, which is likely to be
caused by DN, is not an indication for renal biopsy, as
pathological conﬁrmation of DN rarely provides additional
information regarding the management of patients. However,
several studies have suggested that nondiabetic renal disease
(NDRD) is common in diabetic patients, with the prevalence
ranging from 27% to 79% among patients undergoing renal
biopsy.[4–14] Furthermore, recent studies have shown that the
natural history of DN is substantially changing; the prevalence of
proteinuria is decreasing, whereas the prevalence of reduced renal
function without proteinuria is increasing.[1,15–17] Thus, it is
becoming increasingly important for clinicians to understand the
pathophysiology of DN and to distinguish NDRD from DN
among diabetic patients with chronic kidney disease.
Clinical predictors of NDRD in diabetic patients have been
relatively well established across many studies. These include
short duration of DM, absence of diabetic retinopathy, abrupt
increase in serum creatinine, active urinary sediment, and the
presence of hematuria.[4,5,7,9–14,18,19] Given that the diagnostic
spectrumof primary glomerular disease varieswith proteinuria,
it could be speculated that the types of renal disease and clinical
features of proteinuric patients with DM might be different if
they were classiﬁed according to the amount of proteinuria.
However, proteinuria as a predictor of NDRD showed
inconsistent results. The aims of this study were to identify
clinical predictors of NDRD and to assess whether the
pathological conﬁrmation affects the choice of treatment
modalities and prognosis in diabetic patients with nephrotic-
range proteinuria.2. Materials and methods
2.1. Patient selection and study design
Upon reviewing medical records, we enrolled 220 patients with
type 2 diabetes who underwent renal biopsy at 6 different medical
centers (Kyung Hee University Hospital at Gangdong, Kyung
Hee Medical Center, Konkuk University Medical Center,
Gangnam Severance Hospital, CHA Bundang Medical Center,
and Hanyang University Guri Hospital) from January 2012 to
December 2016. Baseline characteristics and clinical parameters
of enrolled patients according to hospitals are described in
supplementary Table 1, http://links.lww.com/MD/B861. Indica-
tions for renal biopsy included overt proteinuria without diabetic
retinopathy, short duration of DM (<5 y), the presence of active
urinary sediment and/or hematuria, and unexplained decline in
renal function. Patients with nephrotic syndrome, which was
deﬁned by nephrotic-range proteinuria (≥3500mg/d of protein-
uria), pitting edema, hypoalbuminemia, and hypercholesterol-
emia, were also eligible for renal biopsy. Hypoalbuminemia was
deﬁned as levels of serum albumin <3.5g/dL, and hypercholes-
terolemia was deﬁned as levels of serum total cholesterol >2602mg/dL or current use of a statin. Patients with inadequate medical
data, insufﬁcient biopsy samples, or renal transplant recipients
were excluded in this study.
Age, sex, height, weight, duration of DM, and the presence of
hypertension were recorded, and routine laboratory analyses
including HbA1c, hemoglobin, serum albumin, creatinine, and
total cholesterol were also collected at the time of renal biopsy.
Diabetic retinopathy was diagnosed by experienced ophthalmol-
ogists at each hospital. Urine was evaluated for the presence
of hematuria and proteinuria. The presence of hematuria
was deﬁned by 5 or more red blood cells in 1 high-power ﬁeld.
The amount of proteinuria was measured by 24-hour urine
collection, if possible, or calculated as spot urine protein-
to-creatinine ratio (PCR, mg/gCr). Serum creatinine was
standardized with calibration traceable to an isotope-dilution
mass spectrometry reference measurement procedure at each
hospital, and the estimated glomerular ﬁltration rate (eGFR)
was calculated by the Modiﬁcation of Diet in Renal Disease
(MDRD) Study equation: 175 (Scr)–1.154 (Age)–0.203
(0.742, if female). The institutional review board (IRB) from
each hospital approved this study.2.2. Pathological analyses and pathological classiﬁcations
of enrolled patients
All biopsy specimens were processed by standard methods for
routine analyses by light microscopy, immunoﬂuorescence, and
electron microscopy, and were subsequently examined by expert
pathologists at each hospital. Pathologic diagnosis of DN was
made based on the following criteria [20]: diffuse thickening of the
glomerular basement membrane (>395nm in females and >430
nm in males) and mesangial expansion with or without nodular
glomerulosclerosis, which all remained unexplained by other
glomerular diseases.
Depending on the pathological ﬁndings, patients were divided
into the following 3 groups: group I, isolated DN; group II,
NDRD superimposed on DN; and group III, isolated NDRD.2.3. Follow-up and renal outcome
Patients diagnosed with isolated DN received conservative
management without immunosuppressive agents, unless other
indications were present. Patients with NDRD superimposed
on DN or isolated NDRDwere treated according to the Kidney
Disease Improving Global Outcomes (KDIGO) practical
guidelines on glomerulonephritis.[21] Patients visited outpatient
clinics regularly for the assessment of renal function and
proteinuria. Renal outcome was assessed by progression to
ESRD.2.4. Statistical analysis
All statistical analyses were performed with SPSS forWindows,
version 20.0 (SPSS, Chicago, IL). Baseline clinical data are
expressed as the mean± SD or as the numbers of patients and
percentages. Independent t tests, analysis of variance
(ANOVA), and x2 tests were used to compare baseline
characteristics and laboratory ﬁndings, as appropriate. Multi-
ple logistic regression analysis was used to assess the clinical
predictors of NDRD and prognostic factors of renal outcomes.
Finally, a time-to-event analysis for ESRD was performed with
a log-rank test. P values <.05 were considered statistically
signiﬁcant.
Table 1
Comparison of clinical features and laboratory ﬁndings between
diabetic patients with nephrotic-range proteinuria and those with
non-nephrotic-range proteinuria.
Patients with
nephrotic-range
proteinuria (n=129)
Patients with
non-nephrotic-range
proteinuria (n=91) P
Age, y 57.6±12.3 57.4±13.1 .921
Sex (male, %) 75 (58.1) 50 (54.9) .638
BMI, kg/m2 25.2±4.1 25.5±4.1 .685
Duration of DM, y 10.2±8.1 8.9±7.2 .223
Hypertension (n, %) 113 (87.6) 72 (79.1) .090
Diabetic retinopathy (n, %) .201
No 61 (47.3) 51 (56.0)
Yes 68 (52.7) 40 (44.0)
HbA1c, % 7.3±2.0 7.3±1.5 .975
Hemoglobin, g/dL 11.7±9.4 11.5±2.8 .908
Creatinine, mg/dL 2.27±1.83 2.33±2.21 .864
eGFR, mL/min 46.8±34.9 47.6±30.5 .914
Albumin, g/dL 2.93±0.67 3.76±0.66 <.001
Total cholesterol, mg/dL 223.9±96.4 163.8±51.5 <.001
Urine PCR, mg/gCr 10008±7307 1581±979 <.001
Hematuria (n, %) .189
No 65 (50.4) 54 (59.3)
Yes 64 (49.6) 37 (40.7)
Pathologic diagnosis
∗
(n, %) <.001
Group I 81 (62.8) 33 (36.3)
Group II 17 (13.2) 3 (3.3)
Group III 31 (24.0) 55 (60.4)
Data are expressed as mean±SD or number of patients (percentage).
BMI=body mass index, DM=diabetes mellitus, eGFR=estimated glomerular ﬁltration rate, HbA1c=
glycosylated hemoglobin, PCR=protein-to-creatinine ratio.
∗
Group I, isolated diabetic nephropathy; group II, nondiabetic renal disease superimposed on diabetic
nephropathy; group III, isolated nondiabetic renal disease.
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3.1. Baseline demographics and clinical characteristics
of enrolled patients
Table 1 summarizes the baseline demographics and clinical
characteristics of the enrolled patients. We ﬁrst divided patients
according to the amount of proteinuria: patients with heavyTable 2
Nondiabetic renal diseases among patients in group II and III.
Patients with nephrotic-range proteinuria (n=
Group II
∗
(n=17) Group III
∗
(n=31)
Membranous nephropathy 9 11
IgA nephropathy 3 4
MCD 1 4
Crescentic glomerulonephritis 1 2
MPGN 0 3
FSGS 1 1
PIGN 1 1
Hypertensive nephrosclerosis 0 1
Lupus nephritis 0 1
Acute interstitial nephritis 0 0
Acute tubular necrosis 0 0
Others
∗∗
1 3
FSGS= focal segmental glomerulosclerosis, MCD=minimal change disease, MPGN=membranoprolifer
∗
Group II, nondiabetic renal disease superimposed on diabetic nephropathy; Group III, isolated nondiab
∗∗
Others include hypertensive nephrosclerosis, non-IgA mesangial proliferative glomerulonephritis, nons
3proteinuria (urine PCR >3500mg/gCr, n=129) with an average
urine PCR of 10,008mg/gCr, and those with mild-to-moderate
proteinuria (urine PCR <3500mg/gCr, n=91) with an average
urine PCR of 1581mg/gCr. The mean age, sex, body mass index,
mean duration of diabetes, and the prevalence of diabetic
retinopathy showed no difference between groups. However,
serum albumin was signiﬁcantly lower, and total cholesterol was
higher in patients with heavy proteinuria compared with those
with mild-to-moderate proteinuria (2.93 vs 3.76g/dL, P< .001
and 223.9 vs 163.8mg/dL, P< .001, respectively). Renal function
at presentation was similar, with mean eGFR of 46.8mL/min in
patients with heavy proteinuria and 47.6mL/min in those with
mild-to-moderate proteinuria. The prevalence of hematuria was
also similar in both groups.3.2. The prevalence and clinical characteristics of NDRD
among patients with DM
Pathological analyses revealed that isolated DN (group I) was
diagnosed in 114 patients (81 patients with heavy proteinuria and
33 patients withmild-to-moderate proteinuria) (Table 1). Twenty
patients were diagnosed with NDRD superimposed on DN
(group II) (17 patients with heavy proteinuria and 3 patients with
mild-to-moderate proteinuria), and 86 patients were diagnosed
with isolated NDRD (group III) (31 patients with heavy
proteinuria and 55 patients with mild-to-moderate proteinuria).
Overall, the prevalence of NDRD signiﬁcantly differed according
to the amount of proteinuria. Isolated DN was more common in
patients with heavy proteinuria (81/129, 62.8%), whereas
isolated NDRD was more common in patients with mild-to-
moderate proteinuria (55/91, 60.4%). Pathological types of
NDRD in groups II and III are listed in Table 2. Membranous
nephropathy was the most commonly diagnosed NDRD among
patients with heavy proteinuria. However, IgA nephropathy was
the most common type of NDRD among patients with mild-to-
moderate proteinuria. There was no case of crescentic IgA
nephropathy, and all cases of crescentic glomerulonephritis were
caused by antineutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitis.
Table 3 shows the clinical features and laboratory ﬁndings of
patients according to the amount of proteinuria and pathological
classiﬁcations. The mean duration of DM did not differ across48) Patients with non-nephrotic-range proteinuria (n=58)
Total Group II
∗
(n=3) Group III
∗
(n=55) Total
20 1 3 4
7 0 15 15
5 0 1 1
3 0 6 6
3 0 0 0
2 0 2 2
2 0 1 1
1 0 4 4
1 0 1 1
0 0 7 7
0 1 5 6
4 1 10 11
ative glomerulonephritis, PIGN=post infectious glomerulonephritis.
etic renal disease.
peciﬁc focal effacement of foot process, and myeloma cast nephropathy.
Table 3
Clinical features and laboratory ﬁndings of patients according to the degree of proteinuria and pathologic classiﬁcations.
Patients with nephrotic-range proteinuria (n=129) Patients with non-nephrotic-range proteinuria (n=91)
Group I
∗
(n=81)
Group II
∗
(n=17)
Group III
∗
(n=31) P
Group I
∗
(n=33)
Group II
∗
(n=3)
Group III
∗
(n=55) P
Age, y 55.5±11.9 60.3±9.9 61.7±13.4 .034 59.3±10.9 60.7±18.6 56.1±14.1 .495
Sex (male, %) 50 (61.7) 9 (52.9) 16 (51.6) .560 24 (72.7) 2 (66.7) 26 (47.3) .062
BMI, kg/m2 25.0±3.7 26.1±5.6 25.3±4.3 .621 24.5±4.3 22.9±1.4 26.2±4.0 .110
Duration of DM, y 10.9±8.0 11.4±8.1 7.7±7.9 .145 12.4±6.1 8.0±7.9 7.0±7.2 .003
Hypertension (n, %) 73 (90.1) 16 (94.1) 24 (77.4) .129 27 (81.8) 3 (100.0) 42 (76.4) .517
Diabetic retinopathy (n, %)
No 22 (27.2) 14 (82.4) 25 (80.6) <.001 8 (24.2) 2 (66.7) 41 (74.6) <.001
Yes 59 (72.8) 3 (17.6) 6 (19.4) 25 (75.8) 1 (33.3) 14 (25.5)
Clinical manifestation
of nephrotic syndrome (n, %)
16 (19.8) 7 (41.2) 15 (48.4) .006 — — — —
HbA1c, % 7.6±2.3 6.2±0.8 6.8±1.1 .011 7.6±1.7 7.0±1.4 7.1±1.4 .274
Hemoglobin, g/dL 11.6±11.7 11.2±2.3 12.0±2.7 .961 11.0±2.6 11.9±2.0 11.8±2.9 .446
Creatinine, mg/dL 2.55±1.98 2.58±1.86 1.39±0.94 .008 2.82±2.55 2.20±2.44 2.03±1.96 .267
eGFR, mL/min 38.8±26.0 43.5±38.5 69.3±43.6 <.001 35.3±21.0 49.7±40.8 54.8±32.9 .013
Albumin, g/dL 2.95±0.65 3.15±0.51 2.77±0.76 .163 3.60±0.73 3.97±0.96 3.85±0.60 .211
Total cholesterol, mg/dL 208.3±73.9 226.8±97.8 264.0±133.8 .025 161.4±52.2 142.0±17.0 166.1±52.3 .767
Urine PCR, mg/gCr 9013±6030 13360±11468 10807±7234 .074 1845±1010 2021±1132 1404±931 .135
Hematuria
No 44 (54.3) 6 (35.3) 15 (48.4) .350 23 (69.7) 2 (66.7) 29 (52.7) .116
Yes 37 (45.7) 11 (64.7) 16 (51.6) 10 (30.3) 1 (33.3) 26 (47.3)
Data are expressed as mean±SD or number of patients (percentage).
BMI=body mass index, DM=diabetes mellitus, eGFR=estimated glomerular ﬁltration rate, HbA1c=glycosylated hemoglobin, PCR=protein-to-creatinine ratio.
∗
Group I, isolated diabetic nephropathy; group II, nondiabetic renal disease superimposed on diabetic nephropathy; group III, isolated nondiabetic renal disease.
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group I vs II vs III; P= .145). This is in contrast to the ﬁndings of
patients with mild-to-moderate proteinuria, for which mean
duration of DM in the isolated DN groupwas signiﬁcantly longer
than those in the NDRD superimposed on DN and isolated
NDRD groups (12.4 vs 8.0 vs 7.0 y, group I vs II vs III; P= .003).
Diabetic retinopathy was more frequently diagnosed in the
isolated DN group (72.8% vs 17.6% vs 19.4%, group I vs II vs
III; P< .001 in patients with heavy proteinuria and 75.8% vs
33.3% vs 25.5%, group I vs II vs III; P< .001 in patients with
mild-to-moderate proteinuria). eGFR was lower in patients with
isolated DN regardless of the amount of proteinuria (38.8 vs 43.5
vs 69.3mL/min, group I vs II vs III; P< .001 in patients with
heavy proteinuria and 35.3 vs 49.7 vs 54.8mL/min, group I vs II
vs III; P= .013 in patients with mild-to-moderate proteinuria).
Poor glycemic control (higher levels of HbA1c) was found in the
isolated DN group, especially among patients with heavy
proteinuria (7.6% vs 6.2% vs 6.8%, P=0.011). Urine PCR
and the prevalence of hematuria showed no difference acrossTable 4
Clinical predictors of nondiabetic renal diseases.
Patients with nephrotic-range proteinuria (n
b-Estimate Adjusted OR 95% CI
Age 0.047 1.048 1.013–1.084
Duration of DM 0.040 0.961 0.910–1.015
Presence of hypertension 1.606 4.984 0.976–25.446
Absence of diabetic retinopathy 2.730 15.33 5.211–45.121
HbA1c 0.444 0.642 0.456–0.904
eGFR 0.020 1.020 1.007–1.033
Presence of hematuria 0.550 0.577 0.262–1.270
Data shown are analyzed after adjustment with age, sex, the presence of hypertension, and eGFR.
CI= conﬁdence interval, DM=diabetes mellitus, eGFR= estimated glomerular ﬁltration rate, HbA1c=gl
4each pathological group. The prevalence of full-blown nephrotic
syndrome in patients with heavy proteinuria was signiﬁcantly
lower in the isolated DN group (19.8% vs 41.2% vs 48.4%,
group I vs II vs III; P=0.006).3.3. Clinical predictors of NDRD
Clinical predictors of NDRD were assessed by multivariate
logistic regression analysis, with all variables adjusted for age,
sex, the presence of hypertension and eGFR (Table 4).
Intriguingly, predictors of NDRDwere different between patients
with heavy proteinuria and those with mild-to-moderate
proteinuria. A shorter duration of DM, which is a well-known
clinical predictor of NDRD, was not associated with NDRD in
patients with heavy proteinuria [odds ratio (OR) 0.961,
conﬁdence interval (CI) 0.910–1.015, P=0.153]. By contrast,
a signiﬁcant correlation between short duration of DM and the
probability of NDRD was observed in patients with mild-to-
moderate proteinuria (OR 0.898, CI 0.840–0.960, P= .002).=129) Patients with nonnephrotic-range proteinuria (n=91)
P b-Estimate Adjusted OR 95% CI P
.006 0.019 1.020 0.972–1.069 .423
.153 0.108 0.898 0.840–0.960 .002
.053 0.446 1.562 0.529–4.608 .419
<.001 2.694 14.79 3.520–62.112 <.001
.011 0.280 0.756 0.531–1.075 .120
.002 0.036 1.037 1.014–1.059 .001
.577 0.727 0.483 0.169–1.381 .175
ycosylated hemoglobin, OR= odds ratio.
Table 5
Management and renal outcomes of patients.
Patients with nephrotic-range proteinuria (n=129) Patients with non-nephrotic-range proteinuria
∗∗∗
(n=88)
Group I
∗
(n=81)
Group II
∗
(n=17)
Group III
∗
(n=31) P
Group I
∗
(n=33)
Group III
∗
(n=55) P
Duration of follow up, mo 20.2±13.5 26.1±14.5 19.0±12.6 .248 21.5±14.5 23.9±16.0 .507
Use of ARB or ACEi (n, %) 70 (86.4) 12 (70.6) 24 (77.4) .220 25 (75.8) 35 (63.6) .237
Use of immunosuppressant (n, %) 3 (3.7) 7 (41.2) 20 (64.5) <.001 0 (0) 11 (20.0) .006
Annual changes of eGFR, mL/min/y 10.41±11.42 5.62±12.71 4.35±14.33 .013 4.5±6.3 3.4±11.6 .003
Progression to ESRD
∗∗
(n, %) 26/65 (40.0) 3/14 (21.4) 0/28 (0) <.001 10/30 (33.3) 1/41 (2.4) .004
Data are expressed as mean±SD or number of patients (percentage).
ARB= angiotensin receptor blocker, ACEi= angiotensin-converting enzyme inhibitor, eGFR= estimated glomerular ﬁltration rate, ESRD= end-stage renal disease.
∗
Group I, isolated diabetic kidney disease; group II, nondiabetic renal disease superimposed on diabetic kidney disease; group III, isolated nondiabetic renal disease.
∗∗
Patients with follow-up period of <6 months were excluded in this analysis.
∗∗∗
Group II was excluded from the analysis because the number of patients was too small to be analyzed.
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heavy proteinuria, whereas this association was not found in
those with mild-to-moderate proteinuria (OR 1.048, CI
1.013–1.084, P= .006 and OR 1.020, CI 0.972–0.069, P= .423,
respectively). The absence of diabetic retinopathy was a strong
clinical predictor of NDRD, in accordance with the previous
studies (OR 15.33, CI 5.211–45.121, P< .001 in patients with
heavy proteinuria and OR 14.79, CI 3.520–62.112, P<0.001 in
patients with mild-to-moderate proteinuria). Less severe renal
impairment was also an independent predictive factor of NDRD
regardless of the amount of proteinuria (OR 1.020, CI
1.007–1.033, P= .002 in patients with heavy proteinuria and
OR 1.037, CI 1.014–1.059, P= .001 in patients with mild-to-
moderate proteinuria).Figure 1. Renal outcomes of enrolled patients according to the degree of
proteinuria and pathologic classiﬁcation. (A) Renal survival in patients with
nephrotic-range proteinuria, and (B) renal survival in patients with non-
nephrotic-range proteinuria.
∗
Group I, isolated diabetic nephropathy; group II,
nondiabetic renal disease superimposed on diabetic nephropathy; group III,
isolated nondiabetic renal disease.
∗∗
Group II was excluded from the analysis
because the number of patients was too small to be analyzed.3.4. Treatment modality and renal outcomes of patients
Further management and renal outcomes after kidney biopsy are
summarized in Table 5. Among patients with mild-to-moderate
proteinuria, group II was excluded from the analysis because the
number of patients was too small to be analyzed. Two patients
who were diagnosed with crescentic glomerulonephritis in group
III died of severe infection during treatment and were not
included in the outcome analysis.
Mean duration of follow-up and the use of angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker were
not different among groups. Immunosuppressant, primarily to
control NDRD, were more frequently prescribed in patients
with heavy proteinuria (3.7% vs 56.2%, group I vs II + III;
P< .001 in patients with heavy proteinuria and 0% vs 20.0%,
group I vs III; P= .006 in patients with mild-to-moderate
proteinuria). Annual decline in renal function was more severe
in patients with isolated DN than in other groups, both among
patients with heavy proteinuria and mild-to-moderate protein-
uria (10.41 vs 5.62 vs 4.35mL/min/y, group I vs II vs III;
P= .013 and 4.5 vs 3.4mL/min/y, group I vs III; P= .003,
respectively). The incidence of ESRD was also signiﬁcantly
higher in patients with isolated DN (40.0% vs 21.4% vs 0%,
group I vs II vs III; P< .001 in patients with heavy proteinuria
and 33.3% vs 2.4%, group I vs III; P= .004 in patients with
mild-to-moderate proteinuria; Table 5 and Fig. 1). Renal
outcomes according to the etiology of renal disease were further
analyzed (Supplementary Figure 1, http://links.lww.com/MD/
B861). The overall prognosis of patients with biopsy-proven
DN was poor, with 5-year renal survival rate of around 40%.
Meanwhile, most patients with NDRD showed excellent renal5outcomes irrespective of the types ofNDRD. Finally, analysis of
the prognostic factors of renal outcomes revealed that lower
eGFR and the pathologic diagnosis of DN were signiﬁcantly
associated with the development of ESRD, regardless of
proteinuria (Table 6). Higher HbA1c and severe proteinuria
Table 6
Risk factors of progression to end-stage renal diseases.
Patients with nephrotic-range proteinuria Patients with non-nephrotic-range proteinuria
b-Estimate Adjusted OR 95% CI P b-Estimate Adjusted OR 95% CI P
Age 0.017 0.983 0.935–1.032 .487 0.005 1.005 0.936–1.079 .885
Duration of DM 0.032 0.968 0.899–1.043 .392 0.091 1.096 0.983–1.222 .100
Presence of hypertension 1.660 5.260 0.394–70.150 .209 0.628 1.873 0.288–12.194 .511
HbA1c 0.198 1.219 0.892–1.667 .214 0.669 1.951 1.132–3.363 .016
eGFR 0.093 0.911 0.873–0.951 <.001 0.053 0.949 0.911–0.988 .011
Degree of proteinuria 0.000 1.000 1.000–1.000 .388 0.001 1.001 1.000–1.002 .045
Pathologic diagnosis of isolated
DN compared with isolated NDRD
3.909 49.862 5.569–446.481 <.001 3.403 30.06 2.582–350.027 .007
Presence of hematuria 0.045 1.046 0.338–3.237 .938 0.000 1.000 0.204–4.906 1.000
CI= conﬁdence interval, DM=diabetes mellitus, DN=diabetic nephropathy, eGFR= estimated glomerular ﬁltration rate, HbA1c=glycosylated hemoglobin, NDRD=nondiabetic renal disease, OR=odds ratio.
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proteinuria, but not in those with heavy proteinuria.
4. Discussion
Numerous studies had been published regarding the prevalence,
predictive factors, and clinical outcomes of NDRD in patients
with DM, but the degree of proteinuria has not received
signiﬁcant attention to date. One possible explanation for this is
that proteinuria does not show signiﬁcant differences according
to pathological classiﬁcations in most studies. Moreover, the
amount of proteinuria varied greatly depending on the study
design, ranging from 2000 to 8000mg/d, whichmight result from
different policies, indications for renal biopsy and distinct
prevalence of glomerulonephritis and DM according to ethnic
diversities. Given that the underlying etiology of nephrotic- and
non-nephrotic-range proteinuria differs signiﬁcantly, we hypoth-
esized that it would be reasonable to take a different approach by
considering diabetic patients according to the degree of
proteinuria. In this study, we demonstrated that the prevalence
of NDRD among diabetic patients was signiﬁcantly higher in
patients with mild-to-moderate proteinuria than in patients with
heavy proteinuria. On the contrary, isolated DN was diagnosed
more frequently in patients presenting with heavy proteinuria.
Furthermore, distinctive pathological types of coexisting NDRD
were found between these 2 groups; membranous nephropathy
was the most common type of NDRD in patients with heavy
proteinuria, whereas IgA nephropathy was most commonly
diagnosed in those with mild-to-moderate proteinuria. Taken
together, our data suggest that assessing patients differently by
the amount of proteinuria could yield additional information
regarding the likelihood of NDRD and the necessity for renal
biopsy.
A short duration of DM had been repeatedly shown to be a
strong clinical predictor of NDRD in most studies.[4,5,7,9–14,18,19]
However, our results were partially discordant with previous
studies. A short duration of DM was positively associated with
NDRD in patients with mild-to-moderate proteinuria, whereas
no association was found between the duration of DM and
NDRD in patients with nephritic-range proteinuria. Further-
more, among the patients with isolated DN, mean duration of
DM was even shorter in patients with heavy proteinuria than in
those with mild-to-moderate proteinuria, although a signiﬁcant
difference was not found (10.9 vs 12.4 y, P= .385). These ﬁndings
are very intriguing, as they cannot be explained by the natural
course of DN, which is characterized by a gradual increase in6proteinuria over time. However, recent accumulating evidence
has suggested that the traditional clinical course of DN is
changing. Studies have suggested that the development of
proteinuria and the decline in eGFR may not be sequential
events but rather may have independent pathogeneses, and the
widespread use of medications that block the renin angiotensin
aldosterone system and improve glycemic control may be
responsible for these phenomena.[22–25] Large amounts of
epidemiologic data have also revealed similar results, with a
decreasing incidence of albuminuria in diabetic patients over the
last decades.[1] In our study, the prevalence of isolated DN was
much higher in patients with heavy proteinuria than in those with
mild-to-moderate proteinuria (62.8% vs 36.3%, P< .001).
However, as the natural course of DN continues to change,
the prevalence of isolated DN in diabetic patients with heavy
proteinuria will likely decrease, whereas the relative proportion
of NDRD will increase. Accordingly, renal biopsy should be
recommended more intensively in those patients.
Although numerous investigations had been performed to
determine the predictive factors of NDRD, relatively few studies
have compared the prognosis of diabetic patients with different
pathological features.[4,5,13] It is obvious that the prognosis of
patients with isolated DN is signiﬁcantly worse than that of other
patients, with the risk of progression to ESRD ranging from 30%
to 60% within 3 years after pathological diagnosis.[4,5,13] On the
contrary, it is evident that patients with isolated NDRD exhibit
the best prognosis among diabetic patients, with <10% of
patients progressing to ESRD within 5 years after diagnosis.
However, the prognosis of patients withNDRD superimposed on
DN has shown conﬂicting results. Chang et al and Wong et al
demonstrated that the prognoses of those patients were similar to
the prognoses of patients with isolated DN,[5,13] whereas our data
showed that most of those patients maintained their renal
function throughout the study period. It was difﬁcult to explain
the reasons for this discrepancy, as we could not obtain
information regarding NDRD treatment or changes in clinical
parameters over the course of follow-up in the 2 previous studies.
Further large studies are mandatory to conﬁrm the prognosis of
diabetic patients with combined DN and NDRD.
Speciﬁc types of NDRD and DN may share some identical
pathological features, which makes accurate diagnosis compli-
cated. For example, patients with DN frequently show diffuse
effacement of foot processes, which is also the only pathological
feature of minimal change disease (MCD).[26] In this case, it may
be difﬁcult for clinicians to distinguish isolated DN from MCD
superimposed on DN, unless obvious clinical manifestation
[6] Chong YB, Keng TC, Tan LP, et al. Clinical predictors of non-diabetic
Lee et al. Medicine (2017) 96:36 www.md-journal.comfavors MCD such as abrupt onset of proteinuria and nephrotic
syndrome. Furthermore, early and/or atypical features of DN
may be missed in patients who are diagnosed with isolated
NDRD, as renal biopsy only provides a snapshot of the restricted
area within the entire kidney. Accordingly, disease-speciﬁc
markers for DN and other glomerular diseases are needed to
overcome this problem.
Several limitations of our study should be mentioned.
Currently, selection bias is an inevitable issue because renal
biopsy is not routinely performed in patients with a high
probability of having DN. Previous retrospective studies, which
applied similar indications for renal biopsy, had also demon-
strated that the prevalence of NDRD in diabetic patients was
ranging from 27% to 79%, similar to our study.[4–14] On the
contrary, our results showed that the prevalence of isolated DN
was higher in patients with nephritic-range proteinuria. The
prevalence of NDRD in patients with heavy proteinuria has been
rarely reported. Some clinicians try to undergo renal biopsy to
exclude several primary causes of nephrotic syndrome when
diabetic patients show clear clinical manifestations of nephrotic
syndrome. However, most diabetic patients with heavy protein-
uria tend to be excluded from renal biopsy because “classical
DN” usually implies heavy proteinuria. Taken together, we
concluded that the prevalence of isolated DN would be more
frequent in patients with nephritic-range proteinuria despite
considerable selection bias based on indication for renal biopsy
among diabetic patients with heavy proteinuria.
Another limitation is that we could not evaluate more detailed
pathological subgroups, especially with regard to DN. The
current pathological classiﬁcation of DN was developed by the
Renal Pathology Society,[20] and the clinical relevance of this
classiﬁcation was evaluated in patients with isolated DN.[27]
In conclusion, diabetic patients with nephrotic-range protein-
uria showed a distinctive pattern of clinical parameters as well as
different prevalence of NDRD and clinical predictors of NDRD.
Pathological diagnosis was valuable in predicting renal outcomes
and choosing treatment modalities in patients with heavy and
mild-to-moderate proteinuria. Recent updates on the natural
course of DN will also change our perception and clinical
approach to NDRD, and it is reasonable to more extensively
consider renal biopsy in diabetic patients presenting with heavy
proteinuria.References
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